This information sheet is a brief overview of ustekinumab used to treat Crohn’s Disease.
This information is about ustekinumab in general and is not intended to replace specific advice from your doctor or any other health professional.
For further information, please talk to your doctor or specialist IBD team, or look at the information sheet supplied with your medication, or from the website: medicines.org.uk
Ustekinumab is sometimes known by the brand name ‘Stelara’.
Ustekinumab is used to treat moderate to severe active Crohn’s Disease in adults. You may be given ustekinumab if other treatments, including other biological drugs such as adalimumab or infliximab, have not worked or have caused major side effects.
Ustekinumab belongs to a group of medicines called ‘biological drugs’. Biological drugs are produced by a biological, rather than chemical, process. Ustekinumab is a synthetic (man-made) antibody that is created inside living cells.
Ustekinumab is an anti-Interleukin biological drug. It targets two proteins in the body called interleukin-12 (IL-12) and interleukin-23 (IL-23). IL-12 and IL-23 are naturally produced in the body to help fight infections by temporarily causing inflammation. IL-12 and IL-23 are increased in IBD and contribute to the ongoing, or chronic, inflammation in the digestive system.
Ustekinumab binds to both IL-12 and IL-23 which prevents them from working, helping to relieve inflammation and symptoms. Ustekinumab is known as an ‘immunosuppressant’ because it dampens down the activity of the immune system.
Ustekinumab returned me to remission from my worst flare yet. I was able to go back to work within a month, and gradually return to living a ‘normal’ life.
Everyone responds differently when taking a new medicine, and ustekinumab doesn’t work for everyone. You may feel better as early as three weeks after taking ustekinumab, but most people who respond to ustekinumab start feeling better within six weeks. In some people it could take longer.
If you respond to ustekinumab and have no serious side effects, you may be put onto a planned course of treatment lasting up to a year, after which it may be extended. Your treatment plan will need to be reassessed at least every 12 months to check whether ongoing treatment with ustekinumab is right for you. If you are in stable remission, it may be decided that you can stop taking ustekinumab. But If after stopping treatment you become unwell again, you should have the option to restart. You may be taken off ustekinumab if you have any serious side effects or if you have not responded well enough within 16 weeks of starting your treatment.
The first dose of ustekinumab is given in hospital as a drip into a vein in your arm - an intravenous (IV) infusion. The next dose is given as an injection under the skin - a subcutaneous injection 8 weeks later. You will then have further injections every 8 or 12 weeks. Your doctor will decide whether you will need to take ustekinumab every 8 weeks or every 12 weeks.
Ustekinumab comes in a pre-filled syringe and is available in two dosages, 45mg or 90mg. It can’t be taken orally (in tablet form) because your digestive system would destroy it.
To begin with, a doctor or nurse will give you the injections. Once you are used to having the treatment, they will teach you the injection technique so that you can self- inject. If you prefer, it may be possible to train a family member or friend to give the injections.
Ustekinumab will be delivered directly to your home by a home delivery service at a time convenient to you. You must keep ustekinumab in the fridge at all times (between 2-8°C) and ensure it is not exposed to extreme temperatures, for example by freezing it or heating it up. If you are unable to self-inject, the home delivery service can also provide a nurse to visit you at home to administer your injections. Ask your doctor about this service.
One of the most common side effects of ustekinumab is pain and redness at the injection site. These tips can help:
• Allow your medication to warm to room temperature
If you inject yourself with cold ustekinumab straight from the fridge it may be uncomfortable. Try taking it out of the fridge around 15-30 minutes before you take it so it can warm to room temperature. You must not leave ustekinumab out of the fridge for more than 30 minutes. If you think you have left it out of the fridge longer than this, do not use it, put it back in the fridge and contact your IBD team as soon as possible.
• Apply an ice pack before you inject
If you are worried about pain at the injection site you could try applying an ice pack to the area for 2-3 minutes before you inject.
• Clean with an alcohol wipe
Remember to clean the skin with an alcohol wipe before you inject yourself.
• Choose your injection site
The upper thigh or stomach (away from the belly button) are good places for the injection – but avoid any areas where the skin is red, scarred, bruised or hard.
• Use a good injection technique
Use a quick, dart-like motion to insert the needle into the pinched skin. Push the plunger slowly and evenly to inject all of the medicine, keeping pressure on the plunger head and keeping the skin pinched.
• Apply an ice pack after you inject
If your skin at the injection site hurts after you have the injection, it may help to apply an ice pack or cold damp towel to the area for about 10-15 minutes. If you do use an ice pack, place a light towel between it and your skin.
The first dose of ustekinumab is approximately 6mg for every kg you weigh given as a drip into a vein in your arm, an intravenous (IV) infusion.
All following doses are 90mg regardless of what your weight is, and these are all given as an injection under the skin (subcutaneously).
Ustekinumab can be effective in improving symptoms and in bringing about and maintaining remission in people with moderate to severe Crohn’s Disease. This means that the inflammation in your gut is effectively reduced and your symptoms go away or significantly improve. Studies show that around half of those treated benefit from taking ustekinumab. Taking ustekinumab may also mean you no longer have to take steroids.
Some smaller studies suggest ustekinumab may also be effective in treating perianal fistulating Crohn’s Disease. A perianal fistula connects the anal canal (back passage) to the surface of the skin near the anus. You can find out more in our information sheet Living With a Fistula.
Before you start treatment, it is important to make sure that ustekinumab is right for you. Make sure the team treating you know:
• if you have ever had an allergic reaction to ustekinumab or latex (the needle cover of the pre-filled syringe contains latex), or if you are allergic to any of the other ingredients. The ingredients can be found in the Patient Information Leaflet that comes with your medicine, or can be downloaded from medicines.org.uk
• if you have any history of tuberculosis (TB) or any exposure to people with TB. You should not be given ustekinumab if you have active TB. If you have underlying, inactive TB, this will need to be treated before starting ustekinumab.
• if you have a history of infections, currently have an infection or have symptoms such as feeling feverish or generally unwell. If you have an infection your treatment with ustekinumab may need to be postponed.
• if you have a history of cancer. Ustekinumab may slightly increase the risk of developing some types of cancer, such as skin cancer. This hasn’t been seen in studies of people taking ustekinumab for Crohn’s, but may be possible because of how ustekinumab affects the immune system. You may also be at risk even if you do not have a history of cancer.
• if you are having or have ever had injections to treat allergies. It is not known if ustekinumab affects these.
• if you are pregnant, planning to get pregnant, or are breastfeeding.
• if you are taking or have recently taken any other medicines, including other biological drugs such as adalimumab or infliximab or immunosuppressive drugs such as azathioprine, mercaptopurine or methotrexate.
• if you have recently had or will have any vaccinations.
Once your treatment has started you will need regular checks to see whether ustekinumab is working for you. This will also help your doctors prevent any potential complications or catch them at an early stage. Ustekinumab weakens your immune system, so you will also be monitored for signs of infection. Your IBD team will tell you what checks you need and how often. It is important that you tell your doctor or the hospital team monitoring your treatment about any new symptoms you notice, as soon as they occur.
After 12 months of treatment, your IBD team should give you a check-up to see whether you should continue having ustekinumab.
Like all drugs, ustekinumab can have side effects, although not everyone experiences these. Some side effects can happen almost immediately, others may not appear for several days, weeks or even longer. Some side effects are likely to be quite mild and may go away on their own. Others can be more serious and may require treatment, or may mean that ustekinumab is not suitable for you.
Side effects of ustekinumab include the following:
It is not common, but some symptoms may mean you are having an allergic reaction to ustekinumab. Contact your IBD team immediately if you notice any of the following symptoms right after you take ustekinumab, or in the days following an infusion or injection.
• difficutlty breathing or swallowing
• swelling in any part of the body
• dizziness or light-headedness
• redness of the skin, an itchy rash or itchy skin.
• pain in the part of your arm where the infusion needle was inserted
• chills, shivering, or high fever
Other side effects
Ustekinumab weakens the immune system and may make your more likely to get infections. Tell your doctor straight away if you notice any of the following symptoms that may be a sign of infection:
• fever, flu-like symptoms, night sweats
• feeling tired or short of breath
• a cough that won’t go away
• superficial fungal infections
• warm, red, painful skin, or a painful skin rash with blisters
• burning when passing urine
Common side effects that may affect up to 1 in every 10 people taking ustekinumab include:
• sore throat or common cold
• dizziness or headaches
• diarrhoea, nausea or vomiting
• back pain, muscle pain, joint pain
• fatigue or feeling tired
Less commonly, some people taking ustekinumab may develop tooth infections, a blocked nose, depression, bleeding or bruising at the injection site, temporary sagging of the muscles on one side of the face, or women may develop vaginal infections.
Although rare, and not reported for people with Crohn’s, those with psoriasis may develop serious skin conditions called erythrodermic psoriasis or exfoliative dermatitis. Tell your doctor immediately if you notice an increase in redness or shedding of skin over a large area.
It is best to let your doctor or IBD team know about any new symptoms you develop while taking ustekinumab, whenever they occur. They will be able to help you with any queries or concerns.
This is not a complete list of side effects for ustekinumab. For more information see the Patient Information Leaflet provided with your medication, or visit medicines.org.uk
Having ustekinumab on a much more spread out basis (8-12 weeks) means I don’t have the experience of side effects every week after the injection like I did with my previous biologic.
You will need to look out for any of the symptoms listed in the side effects section. Tell your IBD team immediately if you think you are having an allergic reaction.
Ustekinumab affects your immune system, so try to avoid close contact with people who have infections. Contact your doctor if you begin to feel unwell and think you may have caught an infection. It is recommended that you have an annual flu jab.
As ustekinumab is a drug that weakens the immune system, it may theoretically increase your risk of developing some cancers. This hasn’t been seen in studies of people with Crohn’s taking ustekinumab. Ensure you attend routine cancer screening when invited, for example, cervical screening for women (previously known as the smear test).
Tell your doctor or pharmacist if you are taking, have recently taken or might start taking any new medicines. This includes any complementary and alternative medicines. Most other drugs can be taken safely whilst on ustekinumab, but it’s always best to check first. In particular, you should let your doctor or pharmacist know if you currently or have recently been taking any other drugs that weaken the immune system.
Your doctors will advise you on this as they plan your treatment. Immunomodulators such as azathioprine, methotrexate or mercaptopurine
(6-MP) and steroids can be taken during treatment with ustekinumab. See our information sheet on Taking Medicines for more information on taking more than one medicine, which is known as combination therapy.
It is unsafe to have live vaccines while on ustkininumab and for 15 weeks after you stop treatment. You should avoid live vaccines, including BCG (tuberculosis), MMR (measles, mumps and rubella), Varicella-Zoster (chicken pox/shingles), yellow fever and the oral typhoid vaccine.
The annual flu jab is recommended and is safe as it is not a live vaccine, however the nasal spray used for the children’s flu vaccine is live and should not be used if you are taking ustekinumab. See our information sheet Travel and IBD for more information on live vaccines.
Alcohol is not known to have any interaction with ustekiniumab, but for general health reasons it is best to keep within the Department of Health guideline limits.
The effects of ustekinumab on fertility are not yet known. Although ustekinumab did not appear to affect fertility in animal studies, the effect on human fertility has not been studied.
Taking ustekinumab while pregnant is not recommended as the effects of ustekinumab during pregnancy and on the unborn baby are unknown. If you are a woman who could get pregnant, you should use effective contraception while taking ustekinumab, and keep using it for at least 15 weeks after your last dose.
If you are planning a pregnancy, please discuss this with your IBD team first, and if your pregnancy is unplanned, notify your IBD team as soon as possible.
Ustekinumab has been found to pass into breast milk in low levels in animal studies, but it is unknown whether it does the same in humans, or if it may harmful to the baby. Women should speak to their doctor if they are breastfeeding or planning to breastfeed, as breastfeeding should be avoided when taking ustekinumab.
If you are worried about side effects, or have other questions about your ustekinumab treatment, discuss them with your specialist doctor or IBD nurse. They should be able to help you with queries such as why it has been prescribed, what the correct dose and frequency is, what monitoring is in place, what you should do if new symptoms occur, and what alternatives are available.
We offer more than 50 publications on many aspects of Crohn’s Disease, Ulcerative Colitis and other forms of Inflammatory Bowel Disease. You may be interested in our comprehensive booklets on each disease, as well as the following publications:
• Living With Crohn's or Colitis
• Taking Medicines
• Managing Bowel Incontinence
• Living With a Stoma
Health professionals can order some publications in bulk by using our online ordering system. If you would like a printed copy of a booklet or information sheet, please contact our helpline.
Our helpline is a confidential service providing information and support to anyone affected by Crohn's or Colitis. Our team can:
• help you understand more about Crohn's or Colitis, diagnosis and treatment options
• provide information to help you to live well with your condition
• help you understand and access disability benefits
• be there to listen if you need someone to talk to
• put you in touch with a trained support volunteer who has a personal experience of Crohn's or Colitis
Crohn’s & Colitis UK Forum
This closed-group community on Facebook is for everyone affected by Crohn's or Colitis. You can share your experiences and receive support from others.
Crohn’s & Colitis UK Patient Panels
IBD Patient Panels, which are supported by Crohn’s & Colitis UK, are groups of people with Crohn's or Colitis who use their perspective as a patient to work with their IBD healthcare team to help improve their hospital services. For more information on patient panels, please read our information leaflet or contact our Patient Engagement Team.
Crohn’s & Colitis UK Local Networks
Our Local Networks of volunteers across the UK organise events and provide opportunities to get to know other people in an informal setting, as well as to get involved with educational, awareness-raising and fundraising activities. You may find just being with other people and realising that you are not alone can be reassuring. Families and relatives may also find it useful to meet other people with Crohn's or Colitis. All events are open to members of Crohn’s & Colitis UK
Last reviewed: May 2018